Literature DB >> 19631006

Molecular pathogenesis of Parkinson disease: insights from genetic studies.

Thomas Gasser1.   

Abstract

Over the past few years, genetic findings have changed our views on the molecular pathogenesis of Parkinson disease (PD), as mutations in a growing number of genes have been found to cause monogenic forms of the disorder. These mutations cause neuronal dysfunction and neurodegeneration either by a toxic gain of function, as in the case of the dominant forms of monogenic PD caused by mutations in the genes for alpha-synuclein or LRRK2, or by a loss of an intrinsic protective function, as is likely for the recessive PD genes parkin (PRKN), PINK1 and DJ-1. Evidence is emerging that at least some of the pathways uncovered in the rare monogenic forms of PD may play a direct role in the aetiology of the common sporadic disorder and that variants of the respective genes contribute to the risk of developing the disease. These findings will allow the search for new treatment strategies that focus on the underlying molecular pathophysiology, rather than simply on ameliorating symptoms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19631006     DOI: 10.1017/S1462399409001148

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  119 in total

1.  Natural toxins implicated in the development of Parkinson's disease.

Authors:  Mohamed Salama; Oscar Arias-Carrión
Journal:  Ther Adv Neurol Disord       Date:  2011-11       Impact factor: 6.570

Review 2.  Parkinson's disease: insights from pathways.

Authors:  Mark R Cookson; Oliver Bandmann
Journal:  Hum Mol Genet       Date:  2010-04-26       Impact factor: 6.150

Review 3.  Stem cell-based models and therapies for neurodegenerative diseases.

Authors:  Shilpa Iyer; Khaled Alsayegh; Sheena Abraham; Raj R Rao
Journal:  Crit Rev Biomed Eng       Date:  2009

4.  LRRK2 function on actin and microtubule dynamics in Parkinson disease.

Authors:  Loukia Parisiadou; Huaibin Cai
Journal:  Commun Integr Biol       Date:  2010-09

5.  αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction.

Authors:  Becket Greten-Harrison; Manuela Polydoro; Megumi Morimoto-Tomita; Ling Diao; Andrew M Williams; Esther H Nie; Sachin Makani; Ning Tian; Pablo E Castillo; Vladimir L Buchman; Sreeganga S Chandra
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

6.  Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts.

Authors:  Giambattista Guaitoli; Francesco Raimondi; Bernd K Gilsbach; Yacob Gómez-Llorente; Egon Deyaert; Fabiana Renzi; Xianting Li; Adam Schaffner; Pravin Kumar Ankush Jagtap; Karsten Boldt; Felix von Zweydorf; Katja Gotthardt; Donald D Lorimer; Zhenyu Yue; Alex Burgin; Nebojsa Janjic; Michael Sattler; Wim Versées; Marius Ueffing; Iban Ubarretxena-Belandia; Arjan Kortholt; Christian Johannes Gloeckner
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-29       Impact factor: 11.205

7.  Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons.

Authors:  Nigel Ramsden; Jessica Perrin; Zhao Ren; Byoung Dae Lee; Nico Zinn; Valina L Dawson; Danny Tam; Michael Bova; Manja Lang; Gerard Drewes; Marcus Bantscheff; Frederique Bard; Ted M Dawson; Carsten Hopf
Journal:  ACS Chem Biol       Date:  2011-08-10       Impact factor: 5.100

Review 8.  Role of Rab GTPases in membrane traffic and cell physiology.

Authors:  Alex H Hutagalung; Peter J Novick
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 9.  The genetics of Parkinson's disease: progress and therapeutic implications.

Authors:  Andrew B Singleton; Matthew J Farrer; Vincenzo Bonifati
Journal:  Mov Disord       Date:  2013-01       Impact factor: 10.338

Review 10.  The PINK1/Parkin pathway: a mitochondrial quality control system?

Authors:  Alexander J Whitworth; Leo J Pallanck
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.